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Abstract 
Background and Purpose Antiplatelets (APs) may increase the risk of symptomatic 
intracerebral haemorrhage (SICH) following intravenous thrombolysis after ischaemic stroke. 
Methods We assessed the safety of thrombolysis under APs in 11.865 patients compliant 
with the European licence criteria and recorded between 2002-2007 in the SITS International 
Stroke Thrombolysis Register. Outcome measures of uni- and multivariable analyses 
included SICH per SITS-MOST (deterioration in NIHSS ≥4 plus ICH type 2 within 24 h), per 
ECASS-II (deterioration in NIHSS ≥4 plus any ICH), functional outcome at 3 months and 
mortality. 
Results 3782 (31.9%) patients had received one or two AP drugs at baseline: 3016 (25.4%) 
acetylsalicylic acid (ASA), 243 (2.0%) clopidogrel, 175 (1.5%) ASA and dipyridamole, 151 
(1.3%) ASA and clopidogrel, 197 (1.7%) others. Patients receiving APs were 5 years older 
and had more risk factors than AP naïve patients. Incidences of SICH per SITS-MOST 
(ECASS-II) were as follows: 1.1% (4.1%) AP naïve, 2.5% (6.2%) any AP, 2.5% (5.9%) ASA, 
1.7% (4.2%) clopidogrel, 2.3% (5.9%) ASA and dipyridamole, 4.1% (13.4%) ASA and 
clopidogrel. In multivariable analyses, the combination of ASA and clopidogrel was 
associated with increased risk for SICH per ECASS-II (OR 2.11, 1.29-3.45, P=0.003). 
However, we found no significant increase in the risk for mortality or poor functional outcome, 
irrespective of the AP subgroup or SICH definition.  
Conclusion The absolute excess of SICH of 1.4% (2.1%) in the pooled AP group is small 
compared to the benefit of thrombolysis seen in randomised trials. However, caution is 
warranted in patients receiving the combination of ASA and clopidogrel.  
Word count: 254 
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Introduction 
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within the 3-h 
time window is currently one of the approved medical therapies for acute ischaemic stroke. 
Randomised controlled trials have demonstrated the efficacy of intravenous thrombolysis for 
patients up to 4.5 hours after onset of acute ischaemic stroke with acceptable safety profile1-
7
,
 and large observational studies confirm treatment safety in routine clinical practice8, 9. The 
most feared complication of rtPA therapy is symptomatic intracerebral haemorrhage (SICH) 
and concerns have been raised regarding thrombolysis following antiplatelet (AP) treatment 
which patients may be taking prior to stroke. AP drugs impair platelet function and might 
increase the risk of thrombolysis related bleeding.  
Previous analyses of the risk for thrombolysis associated SICH after treatment with 
acetylsalicylic acid (ASA) yielded contradictory results. While some studies found that ASA 10, 
11
 increases the risk for SICH, others do not report an association between ASA co-
medication at stroke onset and the incidence of SICH12-14. The recently published 
multivariable analysis of SITS-MOST (Safe Implementation of Treatments in Stroke-
Monitoring Study) data15 revealed that patients receiving ASA at stroke onset had a 
significantly higher rate of SICH per SITS-MOST definition but not per the NINDS (National 
Institute of Neurological Disorders and Stroke) definition.  
Data on the use of clopidogrel or combined AP treatments prior to thrombolysis is scarce11, 16 
and point towards an increased risk for SICH under dual AP inhibition16. However, no 
detailed analysis of individual AP regimens such as ASA, dipyridamole (DP) and clopidogrel 
(CLP) monotherapy, or combinations of ASA with DP or CLP has been published previously. 
  
We assessed the safety of thrombolysis in patients under various APs at stroke onset using 
data recorded in the prospective SITS International Stroke Thrombolysis Register (ISTR; 
www.acutestroke.org). 
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Methods 
Study population and design 
The SITS database is a world-wide prospective, open, multinational, multicentre audit of 
thrombolysis. Details of data collection and management have been published previously8, 9. 
Datasets include information on baseline and demographic characteristics, risk factors and 
medication history, baseline and follow-up stroke severity measured by NIHSS (National 
Institutes of Health Stroke Scale), baseline and follow-up (at 22-36h) imaging data, 
information on functional outcome as assessed by modified Rankin Scale (mRS) at 3 
months, and primary cause of death. The current analysis is based on the patients within the 
SITS registry strictly fulfilling inclusion and exclusion criteria for thrombolysis according to the 
terms of the rtPA conditional licensing approval. Eligible patients were between 18-80 years 
and received treatment within the 3-hour time window. Exclusion criteria included severe 
stroke defined by NIHSS>25 or by baseline imaging, administration of heparin within the 
previous 48 hours and an elevated thromboplastin time, and prior treatment with oral 
anticoagulants17. Recruitment of patients opened on December 25, 2002, the cut-off for the 
current analysis was November 15, 2007. In the SITS case report form, patients treated with 
ASA, DP, CLP and other APs at stroke onset were recorded. Based on these data we 
defined seven subgroups: 1) ASA only, 2) CLP only, 3) combined ASA and DP, 4) combined 
ASA and CLP, 5) other AP medication (e.g. triflusal), 6) any AP medication and 7) no prior 
use of APs.  
 
Outcome measures 
The main outcome measure was the incidence of SICH according to the SITS-MOST criteria8 
(local or remote parenchymal haemorrhage type 2 on the 22-36 h post-treatment imaging 
scan, combined with a neurological deterioration of 4 points or more compared to baseline 
NIHSS or the lowest NIHSS value between baseline and 24 h). In order to enable 
comparisons with previously published data, two additional definitions were used: 
symptomatic intracerebral haemorrhage per NINDS definition (any haemorrhage plus any 
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neurological deterioration)1 and per ECASS II (European-Australasian Acute Stroke Study) 
definition (any haemorrhage with neurological deterioration, as indicated by an NIHSS score 
≥ 4 than the value at baseline or the lowest value within 7 days, or any haemorrhage leading 
to death)10. Furthermore, functional outcome (mRS 0-1 versus 2-6 for excellent recovery and 
0-2 versus 3-6 for functional independence) and mortality at three months were compared 
between subgroups. 
 
Statistical analysis 
Pearsons χ2 and Mann-Whitney U tests were used for comparisons of categorical and 
continuous variables where appropriate. For assessment of baseline characteristics, each 
AP group was compared to AP naïve patients separately. For categorical variables, 
percentage proportions were calculated by dividing the number of events by the total number 
of patients, excluding missing or unknown cases. Odds ratios for the different outcome 
parameters were calculated using the group without AP treatment as reference group.  
Multivariable analyses were performed in order to account for substantial baseline 
differences between subgroups. For each outcome variable, a separate multivariable 
analysis was performed. AP naïve patients were defined as reference group for calculation of 
odds ratios. All baseline and demographic characteristics shown in Table 1 were included in 
the multivariable model. Multivariable analyses were done by logistic regression analysis. All 
statistical analyses were performed using the STATISTICA software (Version 8.0).  
 
Results 
Population 
Between 2002 and 2007, 11.865 patients receiving thrombolysis according to the European 
rtPA licensing approval were recorded in the SITS-ISTR database. Of these, 3782 (31.9%) 
patients received at least one AP drug (called ‘any AP’) at baseline, 7954 (67.0 %) did not 
receive AP treatment prior to thrombolysis, and for 129 (1.1%) patients data on AP treatment 
were unknown or missing. Of the 3782 patients who received any AP, 3016 (25.4%) received 
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ASA, 243 (2.0%) CLP, 175 (1.5%) ASA and DP, 151 (1.3%) ASA and CLP, and 197 (1.7%) 
other APs. Baseline characteristics and risk factors of the patients separated by AP group 
are listed in Table 1. Patients with AP pretreatment were significantly older (5 years), were 
less likely to be functionally independent prior to stroke, and had a higher incidence of 
cardiovascular risk factors (diabetes, hypertension, AF, previous stroke), compared to those 
without AP therapy. AP treated patients had similar stroke severity, baseline systolic blood 
pressure and onset to treatment times. 
 
Univariate analyses 
The overall incidence of SICH was 1.5% (n=179) per SITS-MOST definition, 7.2% (n=832) 
per NINDS, and 4.8% (n=543) per ECASS II. In AP naïve patients, SICH occurred in 1.1% 
(n=85) according to SITS-MOST definition, in 6.5% (n=507) per NINDS definition and in 
4.1% (n=317) according to ECASS II criteria (Table 2). Patients receiving any AP treatment 
had a risk for SICH of 2.5% (n=94) per SITS-MOST (OR 2.36, 95% CI 1.76-3.17), 8.8% 
(n=325) per NINDS (OR 1.38, 95% CI 1.19-1.60) and 6.2% (n=226, OR 1.53, 95% CI 1.29-
1.82) per ECASS II. Incidence of SICH was highest among the patients receiving a 
combination of ASA and CLP therapy prior to thrombolysis, regardless of the definition (4.1% 
(n=6) per SITS-MOST (OR 3.83, 95% CI 1.65-8.91); 15.2% (n=22) per NINDS (OR 2.51, 
95% CI 1.58-3.97) and 13.4% (n=19) per ECASS II (OR 3.47, 95% CI 2.12-5.68), Table 2).  
 
Distributions of the outcome scores at three months assessed by mRS are presented in 
Figure 1. The proportion of patients with excellent recovery (mRS 0-1) was 41.4% (n=2813) 
in the group without prior AP drug use compared to 37.2% (n=1239) with any AP treatment. 
37.5% (n=998) of patients under ASA and 28.9% (n=39) under ASA and CLP had an 
excellent recovery. Mortality at three months was higher in all AP groups, except for patients 
treated with ASA and DP. 10.6% (n=727) of patients without prior AP treatment had died 
after three months compared to 15.3% (n=515) with any AP treatment. Mortality in the ASA 
and CLP group was 22.8% (n=31) and 15.0% (n=402) under ASA alone, Table 2.  
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Figure 2 shows the rates of fatal SICH (per different definitions) of each subgroup. In addition 
we provide the data derived from the primary causes of death report forms including the 
categories death due to any ICH or the combination of any haemorrhage plus underlying 
ischaemic stroke, and the percentage of patients who had mycocardial infarction or other 
vascular events indicated as primary cause of death. Incidence of fatal ICH regardless of the 
definition or database source was highest among the patients receiving the ASA and CLP 
combination therapy (per SITS: 0.67% (n=1) versus 0.18% (n=14) AP naïve group, 
p=0.1685; per NINDS: 7.28% (n=11) versus 2.16% (n=172), P<0.0001). However, consistent 
with their cardiovascular risk profiles, significantly more patients with ASA and CLP died 
because of myocardial infarction or other vascular events as compared AP naïve patients 
(4.64% (n=7) versus 0.80% (n=64), P<0.0001).  
 
 
Multivariable analyses 
In order to account for substantial differences in baseline and demographic characteristics 
between groups, multivariable logistic regression analyses were performed. Comparing any 
AP treatment versus no AP treatment, significantly higher odds were found for SICH per 
SITS MOST definition (OR 1.28, 95% CI 1.08-1.52, P=0.0052). However, treatment with any 
AP was neither associated with higher odds for SICH per NINDS or ECASS II definitions, nor 
with mortality or poor functional outcome (Figure 3).  
 
The adjusted analysis of the different AP groups only revealed the combination of ASA plus 
CLP as a significant predictor for SICH compared to AP naïve patients per NINDS (OR 1.74, 
95% CI 1.11-2.73, P=0.0167) definition and per ECASS II definition (OR 2.11, 95% CI 1.29- 
3.45, P=0.0031), but not per SITS-MOST criteria (Figure 3). There was no statistically 
significant difference in the multivariable analyses regarding odds for excellent recovery 
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(mRS 0-1), independence for activities of daily living (mRS 0-2) or mortality at three months 
between the different AP subgroups and AP naïve patients (Figure 3). 
 
Discussion 
This observational study provides evidence that AP therapy after adjustment for baseline 
characteristics does not substantially increase the risk for SICH in patients treated with rtPA 
within three hours of stroke onset and according to the European licensing restrictions. The 
absolute excess of 1.4% of SICH per SITS-MOST definition under AP co-medications 
altogether did not translate into poor functional outcome or a higher mortality rate at 3 
months. Thus, the net benefit of thrombolysis found in randomized controlled trials2 is 
maintained for patients with AP pre-treatment. However, caution should be warranted in the 
subgroup of patients receiving the combination of CLP and ASA at stroke onset. These 
patients had considerably higher rates of SICH, and the risk for SICH according to ECASS-II 
and NINDS definitions remained significantly increased after adjustment for baseline 
characteristics. 
 
This is the largest series of patients investigating safety of thrombolysis on AP therapy so far. 
In accordance with other reports, one third of patients in the SITS registry were treated with 
AP drugs prior to thrombolysis11, 18, 19. As reported previously8, overall incidences of 
symptomatic intracerebral haemorrhages in our cohort were comparable to randomised 
controlled trial populations when similar definitions were used (NINDS 7.2% versus 8.6%; 
ECASS II 8.8% versus 4.8%)1, 7. However, the absolute incidences of SICH varied 
considerably depending on the definition used. While the percentage of SICH in patients 
using ASA and CLP was 4.1% per SITS-MOST definition, it was 13.4% according to ECASS-
II. Yet, the proportional increase in relation to AP naïve patients was comparable for both 
definitions (3.7 fold versus 3.3 fold). So far, there is no study systematically investigating the 
clinical meaningfulness and predictive value in terms of clinical outcomes of the different 
SICH definitions.  
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While treatment with any AP, and specifically ASA and the combination of ASA and CLP was 
associated with higher odds for SICH, poor functional outcome and mortality in univariate 
analyses, only patients receiving dual AP inhibition using ASA and CLP had a significantly 
increased risk for SICH per ECASS-II and NINDS after adjustment for baseline 
characteristics. However, none of the AP regimens was identified as an independent risk 
factor for mortality or poor functional outcome in multivariable analyses, taking into account 
the substantial differences in baseline characteristics between groups. As expected, 
comparison of baseline characteristics confirmed that patients under AP drugs were older 
and frequently had several cardiovascular risk factors. Prior AP therapy was related to age, 
presence of risk factors, and previous vascular events. We thereby conclude that higher 
mortality and poor functional outcome after thrombolysis under AP co-medication is not 
attributable to SICH, but rather to other prognostically relevant factors such as age and co-
morbidities.  
 
In line with our study, a recently published observational single-centre study reported a 
significantly higher risk for SICH following thrombolysis for patients receiving AP therapy11. 
Additionally, in the same study, AP therapy was not associated with poor outcome. In 
contrast, prior AP use was even independently associated with favourable outcome at three 
months. The authors hypothesized that AP treatment may prevent early reocclusion after 
thrombolytic therapy and thereby improve outcome. However, patient numbers were small: a 
total of 301 patients were included, 89 of them having used AP drugs (64 ASA, 22 ASA and 
DP, 1 DP, 1 CLP). The association with AP and favourable outcome in this previous small 
study was not confirmed in our large multi-centre study. However, of potential interest was 
the fact that patients receiving the combination of ASA and DP had the best outcomes in 
terms of functional independence (66.7% versus 57.8% AP naïve patients) and mortality 
(8.5% versus 10.6%), despite of increased incidence of SICH. Although this difference did 
not remain significant after adjustment for baseline characteristics, potentially beneficial 
effects of ASA and DP in combination with rtPA may merit further investigation. The optimal 
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design to investigate whether prior AP may improve outcome after thrombolysis would be a 
randomized controlled trial. Such a trial is currently ongoing in the Netherlands20.  
In a recently published analysis of the SITS-MOST cohort including 6483 patients it has been 
shown that prior ASA treatment increased the risk for SICH per SITS-MOST definition15. In 
the current study, ASA therapy alone did not appear as a significant predictor for any 
definition of SICH. That may be due to the fact that the current cohort was based on SITS-
ISTR population, including additional 5000 patients. Furthermore, the ASA group in the 
former analysis also comprised patients with a combination therapy (ASA and CLP, ASA and 
DP). 
 
While several reports provided data on safety of thrombolysis in patients under treatment 
with ASA10, 12-14, data from large series of patients on pre-treatment with CLP or the 
combination of ASA and DP or ASA and CLP have not been available so far. However, 
previous studies on secondary prevention of ischemic stroke point towards an increased 
bleeding risk for the combination therapy of ASA and CLP21. In addition, a secondary 
analysis of the SAINT trials reports the combination of ASA and CLP to be associated with a 
more than 3-fold increase in SICH16. In our cohort including 11.865 patients, 394 (3.3%) 
patients have been treated with CLP or the combination of ASA and CLP prior to 
thrombolysis. As indicated above, patients under dual platelet inhibition were older and more 
frequently carried cardiovascular risk factors, making them more likely to develop poor 
outcome. After adjustment for baseline characteristics, pre-treatment with CLP alone was not 
an independent predictor of any of the outcome variables. In contrast, in patients receiving 
dual AP inhibition using ASA and CLP the increased risk for SICH according to ECASS-II 
and NINDS definition remained significant after adjustment for baseline characteristics. 
Although this did not translate into worse outcome, the significant increase in SICH rates 
suggests that great caution is demanded performing thrombolysis in this subgroup of 
patients. Prior to decision for thrombolysis, additional factors possibly contributing to SICH 
such as elevated blood pressure should be considered carefully in this subset of patients.  
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In the current study, only patients according to the strictly defined inclusion and exclusion 
criteria of the European rtPA conditional licensing approval were evaluated. Thus, our study 
does not provide information on patients that were treated within an enlarged time-window as 
evaluated in ECASS III 5 or about patients older than 80 years. The recently published 
ECASS-III study, investigating the effect of rtPA in the extended time-window (3-4.5 hours), 
found a net benefit with respect to favourable functional outcome (mRS 0-1) of 7.2% for 
thrombolysis and a rate of sICH per SITS-MOST definition of 1.9% in the active treatment 
group5. However, the effects of AP therapy on benefits from thrombolysis should not be 
extrapolated to patient groups treated outside the current EU Licence criteria such as 
treatment beyond 3 hours and treatment of the very elderly > 80 years. 
In conclusion, these data support the use of thrombolysis in patients taking AP therapy at 
stroke onset. However, the increased risk of SICH associated with the combination of aspirin 
and clopidogrel suggests caution may need to be exercised in use of thrombolysis in this 
group of patients if they are at significantly increased risk of SICH due to other factors. 
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Table 1 Baseline characteristics of patients according to prior AP treatment. For categorical variables results are indicated by 
numbers (%) and for continuous or ordinal variables by median (IQR). p -values indicate comparison of each AP subgroup/ any 
AP versus no AP (Pearson χ2 for categorical and Mann-Whitney U test for continuous or ordinal variables).  
 
 
ASA 
(n=3016) 
CLP 
(n=243) 
ASA+DP 
(n=175) 
ASA+CLP 
(n=151) 
Other AP 
(n=197) Any AP 
No AP 
(n=7954) 
Age (years) 71 (12)*** 72 (12)*** 72 (14)*** 70 (10)*** 72 (11)*** 71 (12)*** 66 (56-73)  
Sex (female) 1062 (35.2)*** 84 (34.6)* 68 (38.8) 45 (29.8)** 67 (34.0)* 1326 (35.1)*** 3276 (41.2) 
mRS 0-1 before 
stroke 2676 (91.4)*** 207 (89.6)** 148 (86.0)*** 130 (89.7)* 170 (91.9) 3331 (91.0)*** 7326 (94.4) 
Hypertension 2208 (74.1)*** 182 (75.2)*** 122 (70.1)*** 122 (81.3)*** 140 (71.8)*** 2774 (74.1)*** 4026 (52.0) 
Diabetes mellitus 596 (20.0)*** 63 (26.1)*** 21 (12.1) 59 (39.3)*** 38 (19.6)* 777 (20.8)*** 1069 (13.7) 
Hyperlipidaemia 1355 (50.0)*** 111 (49.6)*** 109 (66.1)*** 95 (66.4)*** 89 (50.9)*** 1759 (51.4)*** 1844 (26.5) 
Atrial fibrillation 992 (33.6)*** 79 (32.8)*** 23 (13.5) 41 (32.4)** 63 (32.6)*** 1198 (32.3)*** 1409 (18.1) 
Congestive heart 
failure 380 (12.9)*** 30 (12.6)*** 18 (10.4)*** 41 (27.9)*** 19 (9.9)*** 488 (13.2)*** 344 (4.4) 
Smoking 
(current/previous) 
534/690 
(18.9/24.5)*** 
38/66 
(16.7/18.7)*** 
44/29 
(23.4/18.7) 
24/44 
(17.3/31.7)*** 
38/49 
(20.4/26.3)*** 
678/878  
(19.2/ 24.9)*** 
2146/1102 
(28.4/14.6) 
Previous stroke 526 (17.8)*** 95 (39.3)*** 108(61.7)*** 31 (20.7)*** 55 (28.4)*** 815 (21.9)*** 367 (4.7) 
Anti-hypertensive 
treatment 2040 (68.0)*** 160 (65.8)*** 111 (63.8)*** 117 (77.5)*** 127 (64.8)*** 2555 (67.9)*** 2795 (35.3) 
Blood Glucose 
(mg/dl) 119 (40)*** 119 (43) 110 (36)** 119 (50) 119 (48) 118 (40)*** 116 (38)  
Systolic blood 
pressure (mm Hg) 150 (27) 151 (27) 152 (27) 148 (31) 150 (31) 150 (27) 150 (31) 
Diastolic blood 
pressure (mm Hg) 80 (18)*** 80 (20)** 80 (19)** 80 (19)*** 80 (20) 80 (18)*** 82 (15) 
rtPA dose (mg) 70 (14)*** 68 (12) 70 (17) 67 (15) 68 (12) 70 (16)*** 68 (17) 
Weight (kg) 78 (16)*** 75 (13) 77 (16) 75 (17) 75 (13) 77 (15)*** 75 (18) 
Baseline NIHSS  12 (9) 13 (10)* 9 (7)*** 13 (9)* 13 (9)* 12 (9) 12 (9) 
Signs of current 
infarction baseline 
imaging 
650 (21.7)* 47 (19.3) 24 (13.7)* 28 (18.8) 27 (13.9) 776 (20.7) 1561 (19.8) 
Stroke onset to 
treatment time (min) 140 (50) 140 (50) 135 (51) 125 (55)*** 150 (52) 140 (51) 140 (50) 
 
*** P<0.001, ** P<0.01, *P<0.05 
 
 
 19 
Table 2  Univariate analysis of outcome parameters 
 
 ASA CLP ASA+DP ASA+CLP Other AP Any AP No AP 
SICH per 
SITS-MOST1 
n (%) 
OR (95% CI) 
73 (2.5) 4 (1.7) 
1.55 (0.56-4.26) 
4 (2.3) 6 (4.1) 7 (3.7) 94 (2.5) 85 (1.1) 
2.30 (1.67-3.15) 2.17 (0.79-5.97) 3.83 (1.65-8.91) 3.41 (1.56-7.47) 2.36 (1.76-3.17)  
SICH per 
NINDS2 
n (%) 
OR (95% CI) 
255 (8.6) 
1.20 (1.02-1.41) 
16 (6.7) 
1.04 (0.62-1.73) 
12 (6.9) 22 (15.2) 20 (10.5) 325 (8.8) 507 (6.5) 
1.08 (0.60-1.96) 2.51 (1.58-3.97) 1.66 (1.04-2.66) 1.38 (1.19-1.60)  
SICH per 
ECASS II3 
n (%) 
OR (95% CI) 
171 (5.9) 
1.45 (1.20-1.75) 
10 (4.2) 10 (5.9) 19 (13.4) 16 (8.5) 226 (6.2) 317(4.1) 
1.03 (0.54-1.97) 1.46 (0.76-2.79) 3.47 (2.12-5.68) 2.13 (1.26-3.59) 1.53 (1.29-1.82)  
Excellent 
recovery4 
n (%) 
OR (95% CI) 
998 (37.5) 
0.90 (0.83-0.99) 
79 (37.6) 63 (41.2) 39 (28.9) 60 (34.1) 1239 (37.2) 2813 (41.4) 
0.88 (0.67-1.16) 1.03 (0.75-1.40) 0.64 (0.44-0.92) 0.80 (0.59-1.09) 0.89 (0.82-0.97)  
Functional 
independence5 
n (%) 
OR (95% CI) 
1425 (53.6) 
0.92 (0.85-1.00) 
107 (51.0) 102 (66.7) 61 (45.2) 88 (50.0) 1783(53.5) 3922 (57.8) 
0.81 (0.63-1.05) 1.44 (1.06-1.95) 0.70 (0.50-0.97) 0.83 (0.62-1.10) 0.92 (0.85-1.00)  
Mortality at 3m n (%) 
OR (95% CI) 
402 (15.0) 
1.53 (1.34-1.74) 
35 (16.1) 13 (8.5) 31 (22.8) 34 (19.3) 515 (15.3) 727 (10.6) 
1.67 (1.56-2.41) 0.80 (0.45-1.41) 2.57 (1.72-3.84) 2.07 (1.42-3.02) 1.57 (1.39-1.77)  
 
1Local or remote parenchymal haemorrhage type 2 on the 22-36 h post-treatment imaging scan, combined with a neurological deterioration of 4 points or more compared to baseline NIHSS or the lowest    
NIHSS value between baseline and 24 h 
2Any haemorrhage plus any neurological deterioration 
3Any haemorrhage with neurological deterioration, as indicated by an NIHSS score ≥ 4 than the value at baseline or the lowest value within 7 days, or any haemorrhage leading to death 
4
modified Rankin Score (mRS) 0-1 at 3 months 
5
mRS 0-2 at 3 months 
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Figure Legends 
 
Figure 1: Distribution of the scores on the modified Rankin Scale at three months according to AP group, indicated in % and (n).  
 
Figure 2: Causes of death, indicated as percentage of subgroup and n. The discrepancy between the percentage of patients in 
categories (3) and (4) as compared to group (5) are due to the fact that the data was derived from different sources within the 
SITS database (clinical and CT data (2,3,4) and primary cause of death report forms (1,5)).  
 
Figure 3: Adjusted odds ratios for symptomatic intracerebral haemorrhage (SICH) per SITS-MOST, NINDS and ECASS II 
definitions and different outcome measures. 
 
